FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steinman, L.
Right arrow Articles by Mantegazza, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steinman, L.
Right arrow Articles by Mantegazza, R.

The FASEB Journal, Vol 4, 2726-2731, Copyright © 1990 by The Federation of American Societies for Experimental Biology

REVIEWS

Prospects for specific immunotherapy in myasthenia gravis

L Steinman and R Mantegazza
Department of Genetics, Stanford University School of Medicine, California 94305.

Myasthenia gravis is an autoimmune disease resulting from a breakdown in T and B cell tolerance to acetylcholine receptor (AChR). Autoantibodies to AChR mediate the disease. Recent advances in experimental immunotherapy of autoimmune disease provide several possibilities for specific intervention in this well-characterized condition.


This article has been cited by other articles:


Home page
 ScienceHome page
L. Steinman
Immune Therapy for Autoimmune Diseases
Science, July 9, 2004; 305(5681): 212 - 216.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by The Federation of American Societies for Experimental Biology.